vs
FVCBankcorp, Inc.（FVCB）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
FVCBankcorp, Inc.的季度营收约是Protalix BioTherapeutics, Inc.的1.9倍（$16.9M vs $9.1M），FVCBankcorp, Inc.同比增速更快（4377.5% vs -49.9%），FVCBankcorp, Inc.自由现金流更多（$23.8M vs $1.6M），过去两年FVCBankcorp, Inc.的营收复合增速更高（586.6% vs -6.7%）
FVCBankcorp是总部位于美国弗吉尼亚州的银行控股公司，旗下运营社区银行FVCbank，面向大西洋中部地区的中小企业、专业人士及个人客户提供存款、贷款、按揭、财富管理等各类个人及商业银行金融服务。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
FVCB vs PLX — 直观对比
营收规模更大
FVCB
是对方的1.9倍
$9.1M
营收增速更快
FVCB
高出4427.4%
-49.9%
自由现金流更多
FVCB
多$22.2M
$1.6M
两年增速更快
FVCB
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.9M | $9.1M |
| 净利润 | — | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 43.7% | -51.1% |
| 净利率 | — | -60.3% |
| 营收同比 | 4377.5% | -49.9% |
| 净利润同比 | — | -184.8% |
| 每股收益（稀释后） | $0.31 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVCBPLX
| Q4 25 | $16.9M | $9.1M | ||
| Q3 25 | $416.0K | $17.9M | ||
| Q2 25 | $15.8M | $15.7M | ||
| Q1 25 | $382.0K | $10.1M | ||
| Q4 24 | $378.0K | $18.2M | ||
| Q3 24 | $412.0K | $18.0M | ||
| Q2 24 | $415.0K | $13.5M | ||
| Q1 24 | $359.0K | — |
净利润FVCBPLX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $5.6M | $2.4M | ||
| Q2 25 | $5.7M | $164.0K | ||
| Q1 25 | $5.2M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $4.7M | $3.2M | ||
| Q2 24 | $4.2M | $-2.2M | ||
| Q1 24 | $1.3M | — |
毛利率FVCBPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率FVCBPLX
| Q4 25 | 43.7% | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | 45.9% | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
净利率FVCBPLX
| Q4 25 | — | -60.3% | ||
| Q3 25 | 1341.1% | 13.2% | ||
| Q2 25 | 36.0% | 1.0% | ||
| Q1 25 | 1352.1% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 1133.3% | 18.0% | ||
| Q2 24 | 1001.2% | -16.4% | ||
| Q1 24 | 373.3% | — |
每股收益（稀释后）FVCBPLX
| Q4 25 | $0.31 | $-0.06 | ||
| Q3 25 | $0.31 | $0.03 | ||
| Q2 25 | $0.31 | $0.00 | ||
| Q1 25 | $0.28 | $-0.05 | ||
| Q4 24 | $0.27 | $0.10 | ||
| Q3 24 | $0.25 | $0.03 | ||
| Q2 24 | $0.23 | $-0.03 | ||
| Q1 24 | $0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $253.6M | $48.2M |
| 总资产 | $2.3B | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FVCBPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
股东权益FVCBPLX
| Q4 25 | $253.6M | $48.2M | ||
| Q3 25 | $249.8M | $52.9M | ||
| Q2 25 | $243.2M | $49.9M | ||
| Q1 25 | $242.3M | $45.2M | ||
| Q4 24 | $235.4M | $43.2M | ||
| Q3 24 | $230.8M | $32.4M | ||
| Q2 24 | $226.5M | $28.6M | ||
| Q1 24 | $220.7M | — |
总资产FVCBPLX
| Q4 25 | $2.3B | $82.3M | ||
| Q3 25 | $2.3B | $82.3M | ||
| Q2 25 | $2.2B | $78.5M | ||
| Q1 25 | $2.2B | $73.9M | ||
| Q4 24 | $2.2B | $73.4M | ||
| Q3 24 | $2.3B | $61.6M | ||
| Q2 24 | $2.3B | $91.5M | ||
| Q1 24 | $2.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.9M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $23.8M | $1.6M |
| 自由现金流率自由现金流/营收 | 140.7% | 17.8% |
| 资本支出强度资本支出/营收 | 0.3% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.0M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流FVCBPLX
| Q4 25 | $23.9M | $2.0M | ||
| Q3 25 | $7.6M | $-3.7M | ||
| Q2 25 | $3.3M | $-5.2M | ||
| Q1 25 | $5.4M | $-5.1M | ||
| Q4 24 | $18.2M | $4.0M | ||
| Q3 24 | $4.7M | $4.1M | ||
| Q2 24 | $1.6M | $-3.6M | ||
| Q1 24 | $7.2M | — |
自由现金流FVCBPLX
| Q4 25 | $23.8M | $1.6M | ||
| Q3 25 | $7.6M | $-4.2M | ||
| Q2 25 | $3.3M | $-5.7M | ||
| Q1 25 | $5.4M | $-5.4M | ||
| Q4 24 | $18.1M | $3.6M | ||
| Q3 24 | $4.6M | $4.0M | ||
| Q2 24 | $1.5M | $-3.8M | ||
| Q1 24 | $7.1M | — |
自由现金流率FVCBPLX
| Q4 25 | 140.7% | 17.8% | ||
| Q3 25 | 1818.0% | -23.7% | ||
| Q2 25 | 20.8% | -36.2% | ||
| Q1 25 | 1413.6% | -53.0% | ||
| Q4 24 | 4786.0% | 19.6% | ||
| Q3 24 | 1121.8% | 22.4% | ||
| Q2 24 | 361.2% | -28.1% | ||
| Q1 24 | 1988.3% | — |
资本支出强度FVCBPLX
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 0.2% | 2.8% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 4.2% | 3.0% | ||
| Q4 24 | 37.3% | 2.3% | ||
| Q3 24 | 14.1% | 0.5% | ||
| Q2 24 | 12.8% | 1.3% | ||
| Q1 24 | 3.9% | — |
现金转化率FVCBPLX
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | -1.58× | ||
| Q2 25 | 0.58× | -31.91× | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 1.00× | 1.27× | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FVCB
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
